-
Start Preamble
AGENCY:
Drug Enforcement Administration, Justice.
ACTION:
Notice of application.
SUMMARY:
Restek Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 24, 2024. Such persons may also file a written request for a hearing on the application on or before May 24, 2024.
ADDRESSES:
The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.33(a), this is notice that on January 31, 2024, Restek Corporation, 110 Benner Circle, Bellefonte, Pennsylvania 16823–8433 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Start Printed Page 20700
Controlled substance Drug code Schedule Gamma Hydroxybutyric Acid 2010 I Methaqualone 2565 I JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) 7118 I JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) 7200 I CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) 7297 I CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) 7298 I Lysergic acid diethylamide 7315 I Marihuana 7360 I Tetrahydrocannabinols 7370 I 4-Methyl-2,5-dimethoxyamphetamine 7395 I 3,4-Methylenedioxyamphetamine 7400 I 3,4-Methylenedioxy-N-ethylamphetamine 7404 I 3,4-Methylenedioxymethamphetamine 7405 I Bufotenine 7433 I Psilocybin 7437 I Psilocyn 7438 I Cyprenorphine 9054 I Dihydromorphine 9145 I Heroin 9200 I Normorphine 9313 I Beta-hydroxyfentanyl 9830 I Beta-hydroxy-3-methylfentanyl 9831 I The company plans to bulk manufacture the listed controlled substances for the Drug Enforcement Administration-exempted certified reference materials. In-house synthesis gives access to compounds that are difficult to source. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.
Start SignatureMarsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–06193 Filed 3–22–24; 8:45 am]
BILLING CODE P
Document Information
- Published:
- 03/25/2024
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of application.
- Document Number:
- 2024-06193
- Dates:
- Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 24, 2024. Such persons may also file a written request for a hearing on the application on or before May 24, 2024.
- Pages:
- 20699-20700 (2 pages)
- Docket Numbers:
- Docket No. DEA-1346
- PDF File:
- 2024-06193.pdf